References
- Bernhagen J., Mitchell R. A., Calandra T., Voelter W., Cerami A., Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 1994; 33: 14144–55
- Leech M., Metz C., Hall P., Hutchinson P., Gianis K., Smith M., et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999; 42: 1601–8
- Meazza C., Travaglino P., Pignatti P., Magni‐Manzoni S., Ravelli A., Martini A., et al. Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46: 232–7
- Burger‐Kentischer A., Goebel H., Seiler R., Fraedrich G., Schaefer H. E., Dimmeler S., et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 2002; 105: 1561–6
- Morand E. F., Leech M., Bernhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 2006; 5: 399–410
- Calandra T., Bernhagen J., Metz C. N., Spiegel L. A., Bacher M., Donnelly T., et al. MIF as a glucocorticoid‐induced modulator of cytokine production. Nature 1995; 377: 68–71
- Bacher M., Metz C. N., Calandra T., Mayer K., Chesney J., Lohoff M., et al. An essential regulatory role for macrophage migration inhibitory factor in T‐cell activation. Proc Natl Acad Sci USA 1996; 93: 7849–54
- Donnelly S. C., Haslett C., Reid P. T., Grant I. S., Wallace W. A., Metz C. N., et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997; 3: 320–3
- Makita H., Nishimura M., Miyamoto K., Nakano T., Tanino Y., Hirokawa J., et al. Effect of anti‐macrophage migration inhibitory factor antibody on lipopolysaccharide‐induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 1998; 158: 573–9
- Ziegler‐Heitbrock H. W. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Immunol Today 1996; 17: 424–8
- Katayama K., Matsubara T., Fujiwara M., Koga M., Furukawa S. CD14+CD16+ monocyte subpopulation in Kawasaki disease. Clin Exp Immunol 2000; 121: 566–70
- Ichiyama T., Yoshitomi T., Nishikawa M., Fujiwara M., Matsubara T., Hayashi T., et al. NF‐κB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol 2001; 99: 373–7
- Daun J. M., Cannon J. G. Macrophage migration inhibitory factor antagonizes hydrocortisone‐induced increases in cytosolic IκBα. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1043–9
- Sundel R. P., Baker A. L., Fulton D. R., Newburger J. W. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003; 142: 611–16
- Inoue Y., Okada Y., Shinohara M., Kobayashi T., Kobayashi T., Tomomasa T., et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006; 149: 336–41